Enjaymo
Named-patient access overview. Enjaymo is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Enjaymo (sutimlimab-jome) is Sanofi's classical complement pathway inhibitor and the first therapy approved by the FDA specifically for hemolysis in adults with cold agglutinin disease. It received FDA approval in February 2022. For Saudi Arabia patients with confirmed cold agglutinin disease and clinically significant hemolysis, this page describes the SFDA Personal Importation Program pathway and what families should expect.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Enjaymo
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Enjaymo is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Enjaymo in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Enjaymo
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.